ANDS- Any particular reason for highlighting Netherlands?
I highlighted it to point out the fact that this was a non-U.S. trial. I think trial integrity is something that doesn't always get a lot of air and, all things being equal, I'd much prefer to see a trial take place in the U.S. (or at least a similarly developed country) than elsewhere. Notwithstanding, the Netherlands isn't exactly a third world country, so it's likely less of an issue here. Furthermore, HCV log drop is a much more objective endpoint than, say, ACR scores in RA patients. So, it's an endpoint that probably would be consistent in either a U.S. or non-U.S. trial.
Market Data 
Markets 
AI
